Activating mutations in the epidermal growth factor receptor (EGFR) are the most common therapeutically tractable driver mutation in lung adenocarcinomas (LUAD) with distinct ethnic differences, occurring at higher frequencies in Asians (40–60%) compared to Caucasians (7–10%)9–12. This evidence concerns the gene EGFR and lung adenocarcinoma.